Evogene (NASDAQ: EVGN) reported Q3 EPS of ($0.08), $0.08 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $3.77 million versus the consensus estimate of $1.2 million.

For earnings history and earnings-related data on Evogene (EVGN) click here.